Capital Research Global Investors Denali Therapeutics Inc. Transaction History
Capital Research Global Investors
- $428 Billion
- Q1 2024
A detailed history of Capital Research Global Investors transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Capital Research Global Investors holds 6,049,957 shares of DNLI stock, worth $128 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
6,049,957
Previous 2,909,528
107.94%
Holding current value
$128 Million
Previous $62.4 Million
98.83%
% of portfolio
0.03%
Previous 0.02%
Shares
7 transactions
Others Institutions Holding DNLI
# of Institutions
217Shares Held
115MCall Options Held
142KPut Options Held
90.3K-
Baillie Gifford & CO14MShares$298 Million0.23% of portfolio
-
Black Rock Inc. New York, NY12.2MShares$259 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11MShares$232 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA8.27MShares$175 Million0.03% of portfolio
-
State Street Corp Boston, MA6.32MShares$134 Million0.01% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.84B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...